Immix Biopharma (IMMX) Cash from Investing Activities (2021 - 2026)
Immix Biopharma (IMMX) posted Cash from Investing Activities of -$4.8 million for Q1 2026, up 27.76% sequentially from -$6.6 million in Q4 2025, and down 6989.98% YoY from $69678.6 in Q1 2025.
Immix Biopharma (IMMX) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Cash from Investing Activities for 5 years, with the latest figure at -$4.8 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 6989.98% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.9 million (down 1166.26% YoY) and the FY2025 annual result came in at -$7.2 million, down 512.54% from the prior year.
- Cash from Investing Activities advanced to -$4.8 million in Q1 2026 per IMMX's latest filing, from -$6.6 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$13177.0 in Q4 2023 and troughed at -$6.6 million in Q4 2025.
- A 4-year average of -$1.3 million and a median of -$286727.5 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities surged 77.57% in 2025, then sank 6989.98% in 2026.
- Over 4 years, Cash from Investing Activities stood at -$13177.0 in 2023, then plunged by 3748.76% to -$507151.0 in 2024, then slumped by 1210.46% to -$6.6 million in 2025, then increased by 27.76% to -$4.8 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$4.8 million, -$6.6 million, and -$372456.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 2.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.67 Mn |
| Jun 30, 2026 | 2.67 Mn |
| Mar 31, 2026 | -4.80 Mn |
| Mar 31, 2026 | -4.80 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Sep 30, 2025 | -372,456.00 |
| Sep 30, 2025 | -372,456.00 |
| Jun 30, 2025 | -127,630.00 |
| Jun 30, 2025 | -127,630.00 |
| Mar 31, 2025 | -67,713.00 |
| Mar 31, 2025 | -67,713.00 |
| Dec 31, 2024 | -507,151.00 |
| Dec 31, 2024 | -507,151.00 |
| Sep 30, 2024 | -271,542.00 |
| Sep 30, 2024 | -271,542.00 |
| Jun 30, 2024 | -97,074.00 |
| Jun 30, 2024 | -97,074.00 |
| Mar 31, 2024 | -301,913.00 |
| Mar 31, 2024 | -301,913.00 |